Amir Tavakkol
Chief Tech/Sci/R&D Officer at Timber Pharmaceuticals LLC
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Joe Lucchese | M | 57 |
Timber Pharmaceuticals LLC
 Timber Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Timber Pharmaceuticals LLC engages in the provision of biopharmaceutical services. It offers congenital ichthyosis, tuberous sclerosis complex, and localized scleroderma. The company was founded in 2019 and is headquartered in Woodcliff Lake, NJ. | 4 years |
| Jeffrey Aronin | M | 56 |
Castle Creek Biosciences, Inc.
 Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | 6 years |
| David Cohen | M | 59 | 4 years | |
| Lubor Gaal | M | 56 | 4 years | |
| Michael Derby | M | 51 |
Timber Pharmaceuticals LLC
Timber Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Timber Pharmaceuticals LLC engages in the provision of biopharmaceutical services. It offers congenital ichthyosis, tuberous sclerosis complex, and localized scleroderma. The company was founded in 2019 and is headquartered in Woodcliff Lake, NJ. | - |
| Antonio Gracias | M | 53 |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | 6 years |
| Volker Herrmann | M | - |
Viamet Pharmaceuticals, Inc.
 Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | 9 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John Koconis | M | 54 |
Timber Pharmaceuticals LLC
Timber Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Timber Pharmaceuticals LLC engages in the provision of biopharmaceutical services. It offers congenital ichthyosis, tuberous sclerosis complex, and localized scleroderma. The company was founded in 2019 and is headquartered in Woodcliff Lake, NJ. | 5 years |
| Zachary Rome | M | 40 | 2 years | |
| Linda A. Broenniman | F | 67 | - | |
| Steven Swinson | M | - |
The University of Manchester
| 4 years |
| Gregory Licholai | M | 59 |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | 2 years |
| Henryk Kalisz | M | - |
The University of Manchester
| 8 years |
| Panos Andreas Loizou | M | 60 |
The University of Manchester
| 7 years |
| Michael T. Stocum | M | 58 | - | |
| Roger Aston | M | 68 |
The University of Manchester
| 6 years |
| Wai Ching Wong | F | 63 |
The University of Manchester
| 5 years |
| Ibrahim Samih Ibrahim Al-Adham | M | 67 |
The University of Manchester
| 5 years |
| David Poulter | M | 62 |
The University of Manchester
| 3 years |
| Ming Chee Cheung | M | - |
The University of Manchester
| 4 years |
| Cheng Seong Yeoh | M | 61 |
The University of Manchester
| 4 years |
| Johari bin Basri | M | 70 |
The University of Manchester
| 1 years |
| Mark Irwin | M | 59 |
The University of Manchester
| 4 years |
| Kwok Wah Tam | M | 74 |
The University of Manchester
| 1 years |
| Chun Kooi Ng | M | 63 |
The University of Manchester
| 4 years |
| Kwok Fai Lam | M | 59 |
The University of Manchester
| 3 years |
| Steven Mann | M | - |
The University of Manchester
| 3 years |
| Zhi Guo Su | M | 70 |
The University of Manchester
| 3 years |
| Tony Bruno | M | 62 |
The University of Manchester
| 4 years |
| Sjoerd Wadman | M | - |
The University of Manchester
| 3 years |
| Okechukwu John Mbonu | M | 71 |
The University of Manchester
| 3 years |
| Mark Portelli | M | - |
The University of Manchester
| 4 years |
| Richard Fraser-Smith | M | 60 |
The University of Manchester
| 4 years |
| Suneel Gupta | M | 66 |
The University of Manchester
| 3 years |
| Seamus Hatch | M | - |
The University of Manchester
| 3 years |
| Hung Tim Ho | M | 57 |
The University of Manchester
| 4 years |
| Alan Mendelsohn | M | 62 | 3 years | |
| Wai Hong Choi | M | 66 |
The University of Manchester
| 4 years |
| Neoclis Nicolaou | M | 64 |
The University of Manchester
| 4 years |
| Kwai Wing Lai | M | 62 |
The University of Manchester
| 4 years |
| Chee Wai Wong | M | 64 |
The University of Manchester
| 3 years |
| Wai Ming Ng | M | 64 |
The University of Manchester
| 4 years |
| Tay Hock Lau | M | 65 |
The University of Manchester
| 4 years |
| David Rhys Goring-Thomas | M | 59 |
The University of Manchester
| 3 years |
| Ede Dafinone | M | - |
The University of Manchester
| 4 years |
| Trevor Baglin | M | - |
The University of Manchester
| 5 years |
| Giles Dacre Marshall | M | - |
The University of Manchester
| 4 years |
| William Lam | M | 65 |
The University of Manchester
| 4 years |
| Yemisi Ayeni | F | - |
The University of Manchester
| 4 years |
| Malcolm France | M | - |
The University of Manchester
| 4 years |
| S. Shahnawaz Ahmed | M | 63 |
The University of Manchester
| 3 years |
| Shu Min Pang | M | 65 |
The University of Manchester
| 4 years |
| Joe Ryan | M | 59 |
The University of Manchester
| 4 years |
| Rolf Andreas Wikborg | M | 66 |
The University of Manchester
| 4 years |
| Julian Sowerby | M | - |
The University of Manchester
| 2 years |
| Bien Chuan Tan | M | 68 |
The University of Manchester
| 3 years |
| Gregory McMahon | M | 64 |
The University of Manchester
| 4 years |
| Timothy Pennington | M | 63 |
The University of Manchester
| 3 years |
| Richard H. Irving | M | - |
The University of Manchester
| 1 years |
| Michael Stewart Levy | M | 61 |
The University of Manchester
| 4 years |
| Ian Bennett | M | - |
The University of Manchester
| 4 years |
| Chong Keat Chew | M | 63 |
The University of Manchester
| 4 years |
| Helen Walsh | F | - |
The University of Manchester
| 3 years |
| Spiros Jamas | M | 63 |
The University of Manchester
| 4 years |
| Richard D. Katz | M | 60 |
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | 5 years |
| Trevor Civval | M | - |
The University of Manchester
| 4 years |
| Kwun Wan Ng | M | 61 |
The University of Manchester
| 4 years |
| Valerie Smart | F | - |
The University of Manchester
| 4 years |
| Nigel Francis Emmett | M | - |
The University of Manchester
| 3 years |
| Mario Reis | M | 64 |
The University of Manchester
| 4 years |
| Peter George Lutz | M | 63 |
The University of Manchester
| 2 years |
| Cheung Shing Ng | M | 62 |
The University of Manchester
| 4 years |
| Fernando Augusto Rojas Pinto | M | 69 |
The University of Manchester
| 1 years |
| Steven M. Bosacki | M | 66 | - | |
| Webster Dunbar | M | 62 |
The University of Manchester
| 4 years |
| Yew Hiap Koh | M | - |
The University of Manchester
| 4 years |
| Mohamad Khir bin Harun | M | 74 |
The University of Manchester
| 3 years |
| Sui See Yuen | M | 73 |
The University of Manchester
| 1 years |
| Rami Waleed Kamel Hamdallah | M | 65 |
The University of Manchester
| 1 years |
| Chi Ming Lam | M | 65 |
The University of Manchester
| 4 years |
| Ian Gillespie | M | - |
The University of Manchester
| 4 years |
| Nigel Crockett | M | 59 |
The University of Manchester
| 4 years |
| Donald Ncube | M | 76 |
The University of Manchester
| 2 years |
| Alan Butcher | M | - |
The University of Manchester
| 3 years |
| Philip J. Coggins | M | - |
The University of Manchester
| 4 years |
| Ashleigh Palmer | M | 61 |
The University of Manchester
| 3 years |
| George Sebastian Matthew Bullto | M | 64 |
The University of Manchester
| 4 years |
| Brad Williams | M | - |
The University of Manchester
| 4 years |
| Oren Cohen | M | 63 |
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | 8 years |
| Jeremy Chan | M | - |
The University of Manchester
| 4 years |
| Gary A. Officer | M | - |
The University of Manchester
| 4 years |
| Timothy DuVall | M | - |
The University of Manchester
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Israel | 76 | 82.61% |
| United States | 16 | 17.39% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Amir Tavakkol
- Personal Network
